Business
Oncolytics Biotech® Inc. to Participate in the Bloom Burton & Co. Healthcare Investor Conference
Oncolytics Biotech® Inc. to Participate in the Bloom Burton & Co. Healthcare Inve...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. to Participate in the Bloom Burton & Co. Healthcare Investor Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncolytics Biotech® Inc. to Participate in the Bloom Burton & Co. Healthcare Investor Conference\nCanada NewsWire\nCALGARY, April 29, 2016\n\n\n\nCALGARY, April 29, 2016 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) (\"Oncolytics\" or the \"Company\"), will participate in the Bloom Burton & Co. Healthcare Investor Conference in a session on Monday, May 2nd, 2016 at 4:00 pm ET. The conference takes place on May 2nd and 3rd in Toronto, Ontario.\n\nA live audio link to the webcast session will be available at http://wsw.com/webcast/bloomburton/onc or on the company's website at http://www.oncolyticsbiotech.com/news-and-events/events-and-webcasts/. It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.\n\nThe Bloom Burton & Co. Healthcare Investor Conference brings together Canadian, U.S. and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.\n\nAbout Oncolytics Biotech Inc.\n\nOncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.\n\nThe session and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve ...